group-women-sports-teams

Newsroom

Take a look inside our world

Press Releases

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva Releases Q2 2026 Aide Memoire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva to Present at the Goldman Sachs Global Healthcare Conference
View all press releases

Our Stories

Teva scientist interacting with a large green abstract network graphic illustrating biological pathways and potential pathways for business growth. Leadership Global Operations Global Growth Biosimilars

Sustaining Teva’s Generics Powerhouse in the Acceleration Phase

 Teva scientist using microscope working on research for innovative medicines Leadership Research & Development Growth

Step Up Innovation

 Teva scientist looking at stylized DNA strand representing acceleration phase of pivot to growth strategy Leadership Research & Development Growth Innovation

Pivot to Growth: The Acceleration Phase

 Leadership Innovation Neuroscience Growth

Delivering on Growth Engines

 Innovation Growth

Teva in 2025: Innovation drives third consecutive year of growth

 Access to Medicine Sustainability Social Impact

Supporting Healthier Communities

 Evan Lippman, Teva’s Executive Vice President of Business Development Global Innovation Research & Development

“I Think People are Starting to Get That There’s a Lot of Upside at Teva”

 Global Innovation Research & Development Patient Focus

Teva Rise: Accelerating Pharma Innovation Globally

 Sustainability Impact

Using Antibiotics Wisely. Making Them Responsibly.

 Global Innovation Global Operations

Building the Factory of the Future with Augmented Reality

 View all stories

Contacts for Media Inquiries

United States

Email
 
Telephone

Israel & Corporate

Email
 
Telephone

Europe

Email

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com